IRIS
RONCATO, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 652
EU - Europa 218
AS - Asia 93
AF - Africa 15
SA - Sud America 2
Totale 980
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 650
IT - Italia 69
IE - Irlanda 42
SG - Singapore 36
CN - Cina 31
IN - India 21
DE - Germania 18
CH - Svizzera 15
TG - Togo 15
UA - Ucraina 15
FR - Francia 14
FI - Finlandia 11
CZ - Repubblica Ceca 10
AT - Austria 6
GB - Regno Unito 5
SE - Svezia 4
TR - Turchia 4
ES - Italia 3
NL - Olanda 3
BR - Brasile 2
CA - Canada 2
IR - Iran 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
Totale 980
Salva come PNG Salva come JPEG
Città #
Fairfield 69
Chandler 68
Ashburn 58
Dublin 42
Houston 38
Woodbridge 38
Cambridge 32
Seattle 30
Singapore 29
Wilmington 27
Boardman 23
Lomé 15
Zurich 15
Ann Arbor 14
Dearborn 13
Ogden 12
Pune 12
Beijing 10
Brno 10
Dallas 10
Princeton 9
Helsinki 8
Munich 8
Redmond 8
Arezzo 7
Hyderabad 7
Los Angeles 7
Jacksonville 6
Udine 6
Cormons 4
Deiva Marina 4
Izmir 4
London 4
New York 4
Vienna 4
Zoppola 4
Codroipo 3
Cologne 3
Shenzhen 3
Amsterdam 2
Azzano Decimo 2
Des Moines 2
Innsbruck 2
Leawood 2
Madrid 2
Milan 2
Monza 2
Novara 2
Porcia 2
Roccamonfina 2
Romans d'Isonzo 2
San Diego 2
San Giorgio di Nogaro 2
São Paulo 2
Vaestra Froelunda 2
Venice 2
Xi'an 2
Ahmedabad 1
Andover 1
Ardabil 1
Barking 1
Bhubaneswar 1
Caorle 1
Coos Bay 1
Cordenons 1
Delft 1
Fayetteville 1
Frankfurt am Main 1
Fuzhou 1
Genoa 1
Jinan 1
Krakow 1
Monfalcone 1
Nanjing 1
New Albany 1
Norwalk 1
Novokuznetsk 1
Padova 1
Redwood City 1
Romano d'Ezzelino 1
San Mateo 1
Shenyang 1
Toronto 1
Treviso 1
Villafranca di Verona 1
Totale 732
Salva come PNG Salva come JPEG
Nome #
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) 114
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity 91
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 78
null 70
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 63
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 45
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 33
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 30
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk 26
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype 23
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 23
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 23
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 22
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 21
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 21
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy 19
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 19
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 18
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients 18
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? 18
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 17
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 17
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer 15
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 15
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 15
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach 14
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 14
IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 14
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine 13
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 13
The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches 13
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 13
Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice 13
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 13
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients 13
European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology 12
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice 12
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9) 11
Genetic biomarkers for hepatocellular cancer risk in a caucasian population 11
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients 11
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 11
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation 11
Therapeutic drug monitoring for the cancer patient: challenges and opportunities 10
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 10
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 10
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity 9
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 8
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy 8
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 8
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment 8
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy 7
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation 5
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study 4
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines 1
Totale 1.154
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.085
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.085
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020201 0 2 10 52 14 35 25 21 21 13 3 5
2020/2021127 3 6 19 16 8 11 28 11 8 5 7 5
2021/202266 3 5 0 4 2 2 11 0 4 10 14 11
2022/2023318 9 3 4 77 59 70 0 22 45 4 9 16
2023/2024339 31 19 11 4 39 40 21 15 19 31 25 84
2024/202574 54 20 0 0 0 0 0 0 0 0 0 0
Totale 1.154